With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

The US Food and Drug Administration (FDA) has approved Uplizna (inebilizumab-cdon) as the first and only treatment for adults ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from ...

In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), ...